Tevogen Bio (NASDAQ:TVGN) Earns "Buy" Rating from D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of Tevogen Bio (NASDAQ:TVGN - Free Report) in a research note issued to investors on Monday,Benzinga reports. They currently have a $10.00 price objective on the stock.

Tevogen Bio Trading Down 1.0 %

Tevogen Bio stock traded down $0.01 during mid-day trading on Monday, reaching $1.01. The stock had a trading volume of 218,832 shares, compared to its average volume of 5,049,593. Tevogen Bio has a fifty-two week low of $0.26 and a fifty-two week high of $3.09. The stock's 50-day simple moving average is $1.16 and its 200-day simple moving average is $1.30.

Insider Buying and Selling at Tevogen Bio

In related news, insider Neal Flomenberg sold 70,384 shares of the firm's stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $1.09, for a total value of $76,718.56. Following the transaction, the insider now owns 3,898,828 shares of the company's stock, valued at approximately $4,249,722.52. This trade represents a 1.77 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last three months, insiders have sold 406,510 shares of company stock valued at $446,763. Corporate insiders own 56.60% of the company's stock.

Institutional Trading of Tevogen Bio

Institutional investors and hedge funds have recently modified their holdings of the stock. China Universal Asset Management Co. Ltd. purchased a new position in Tevogen Bio during the 4th quarter worth $38,000. JPMorgan Chase & Co. increased its stake in Tevogen Bio by 74.2% in the 4th quarter. JPMorgan Chase & Co. now owns 39,207 shares of the company's stock valued at $40,000 after buying an additional 16,695 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Tevogen Bio by 31.2% during the 4th quarter. Geode Capital Management LLC now owns 451,851 shares of the company's stock worth $465,000 after buying an additional 107,566 shares in the last quarter. Barclays PLC boosted its stake in shares of Tevogen Bio by 39.2% in the 4th quarter. Barclays PLC now owns 45,600 shares of the company's stock worth $48,000 after buying an additional 12,847 shares during the last quarter. Finally, XTX Topco Ltd bought a new position in shares of Tevogen Bio in the fourth quarter valued at approximately $55,000.

About Tevogen Bio

Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.